Identification of an antibody that inhibits SARS-CoV-2

Llamas produce so-called single domain antibodies, which could be particularly well suited to inhibit SARS-CoV-2. The infection biologists at the DPZ contributed to a study in which a single domain antibody was identified that inhibits SARS-CoV-1 and SARS-CoV-2 entry into cells. This antibody or antibodies with similar characteristics could be used for COVID-19 prevention and therapy. The results were published in the leading international journal Cell.

Original publication:

Wrapp et al, Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies, Cell. 2020 May 28;181(5):1004-1015.e15